CN106511452A - Drug composition for treating community-acquired pneumonia - Google Patents

Drug composition for treating community-acquired pneumonia Download PDF

Info

Publication number
CN106511452A
CN106511452A CN201611252847.4A CN201611252847A CN106511452A CN 106511452 A CN106511452 A CN 106511452A CN 201611252847 A CN201611252847 A CN 201611252847A CN 106511452 A CN106511452 A CN 106511452A
Authority
CN
China
Prior art keywords
parts
acquired pneumonia
pharmaceutical composition
treatment
community acquired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611252847.4A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Palm Network Technology Co Ltd
Original Assignee
Zhengzhou Palm Network Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Palm Network Technology Co Ltd filed Critical Zhengzhou Palm Network Technology Co Ltd
Priority to CN201611252847.4A priority Critical patent/CN106511452A/en
Publication of CN106511452A publication Critical patent/CN106511452A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)

Abstract

The invention discloses a drug composition for treating community-acquired pneumonia. The drug composition for treating the community-acquired pneumonia is prepared from the following main raw materials in parts by weight: 4-10 parts of ertapenem, 16-24 parts of radix astragali extract, 4-10 parts of radix puerariae flavones, 2-6 parts of cefixime, 1-3 parts of 3-n-butylphthalide, 0.8-1.4 parts of 3-n-butyl-4,5-dihydrophthalide, 1.5-1.9 parts of sulfoniazide, 1-3 parts of ampicillin and 2-4 parts of swertiamarin. The drug composition has the capability of treating the community-acquired pneumonia, and is strong in pertinence; the raw materials are scientifically mixed, so that the purpose of comprehensive rehabilitation is achieved; and the drug composition treats both symptoms and root causes and is short in course of treatment, quick in effect-taking, small in toxic and side effects and very low in cost.

Description

A kind of pharmaceutical composition for treating community acquired pneumonia
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of pharmaceutical composition for treating community acquired pneumonia.
Background technology
Community acquired pneumonia, refers to the infectious pulmonary parenchyma that trouble is urged outside hospital (containing alveolar wall, i.e., between sensu lato lung Matter) inflammation, including the pneumonia fallen ill within incubation period after people institute with clearly preclinical pathogenic infection.Community-acquired Pneumonia is one of the Common infectious diseases for threatening human health, its pathogenic former composition and resistant characterization in country variant, no Notable difference be there is between area, and As time goes on and constantly changed.
Western medicine mainly adopts second and third generation cephalosporin, beta-lactam class, fluoroquinolones treatment at present, though have certain Curative effect, but with the transition of pathogenic microorganism, drug resistance phenomenon is on the rise, and side effect is larger, and some drugs are expensive, therefore Be difficult to popularity, and Chinese medicine then show in terms of improving symptom and sign, Shorten the Treatment Process and improving overall treatment effect it is huge Big advantage, but curative effect is slower, and long-term taking is big to Liver and kidney harm.
Therefore, it is badly in need of a kind of suitable good effect of research and development, speed is fast, price is low, the Western medicine compound that has no toxic side effect.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating community acquired pneumonia, to solve above-mentioned background The problem proposed in technology.
For achieving the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition for treating community acquired pneumonia, according to the primary raw material of weight portion be：Ertapenem 4- 10 parts, Radix Astragali extract 16-24 parts, Radix Puerariae flavone 4-10 parts, cefixime 2-6 parts, 3-n-butylphthalide 1-3 parts, the positive fourths of 3- Base -4,5- dihydro Phthalide 0.8-1.4 parts, sulfoniazid 1.5-1.9 parts, ampicillin 1-3 parts, swertiamarin 2-4 parts.
As further scheme of the invention：The pharmaceutical composition of the treatment community acquired pneumonia, according to weight portion Primary raw material be：Ertapenem 6-7 parts, Radix Astragali extract 18-22 parts, Radix Puerariae flavone 5-7 parts, cefixime 3-5 parts, 3- are just Butylphthalide 1-3 parts, 3- normal-butyl -4,5- dihydro Phthalide 0.9-1.2 parts, sulfoniazid 1.6-1.8 parts, ampicillin 1-3 parts, Swertiamarin 2-4 parts.
As further scheme of the invention：The pharmaceutical composition of the treatment community acquired pneumonia, according to weight portion Primary raw material be：7 parts of ertapenem, 20 parts of Radix Astragali extract, 6 parts of Radix Puerariae flavone, 4 parts of cefixime, 3-n-butylphthalide 2 Part, 1.0 parts of 3- normal-butyl -4,5- dihydros Phthalide, 1.7 parts of sulfoniazid, 2 parts of ampicillin, 3 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition for treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, Radix Astragali extract, Radix Puerariae flavone, head are weighed by above-mentioned metering ratio Spore gram oxime, 3-n-butylphthalide, 3- Senkyunolide As, sulfoniazid, ampicillin, swertiamarin, sieve, Machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 4-10min, controls RSD≤5%, tabletting low after mixing Temperature is dried, and at 4-10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
As further scheme of the invention：In concrete steps, temperature control is at 6 DEG C.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention has the ability for the treatment of community acquired pneumonia, with strong points, scientific compatibility, so as to reach comprehensively The purpose of rehabilitation, treating both the principal and secondary aspects of a disease, short treating period, instant effect, toxic and side effects are little, and cost is very cheap.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention Embodiment, the every other embodiment obtained under the premise of creative work is not made by those of ordinary skill in the art, all Belong to the scope of protection of the invention.
Embodiment 1
A kind of pharmaceutical composition for treating community acquired pneumonia, according to the primary raw material of weight portion be：Ertapenem 4 Part, 15 parts of Radix Astragali extract, 4 parts of Radix Puerariae flavone, 2 parts of cefixime, 1 part of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydrobenzenes 0.8 part of phthalein, 1.5 parts of sulfoniazid, 1 part of ampicillin, 2 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition for treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, Radix Astragali extract, Radix Puerariae flavone, head are weighed by above-mentioned metering ratio Spore gram oxime, 3-n-butylphthalide, 3- Senkyunolide As, sulfoniazid, ampicillin, swertiamarin, sieve, Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mix 4min, control RSD≤5%, tabletting low temperature after mixing It is dried, at 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 2
A kind of pharmaceutical composition for treating community acquired pneumonia, according to the primary raw material of weight portion be：Ertapenem 6 Part, 18 parts of Radix Astragali extract, 5 parts of Radix Puerariae flavone, 3 parts of cefixime, 1 part of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydrobenzenes 0.9 part of phthalein, 1.6 parts of sulfoniazid, 1 part of ampicillin, 2 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition for treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, Radix Astragali extract, Radix Puerariae flavone, head are weighed by above-mentioned metering ratio Spore gram oxime, 3-n-butylphthalide, 3- Senkyunolide As, sulfoniazid, ampicillin, swertiamarin, sieve, Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mix 4min, control RSD≤5%, tabletting low temperature after mixing It is dried, at 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 3
A kind of pharmaceutical composition for treating community acquired pneumonia, according to the primary raw material of weight portion be：Ertapenem 7 Part, 20 parts of Radix Astragali extract, 6 parts of Radix Puerariae flavone, 4 parts of cefixime, 2 parts of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydrobenzenes 1.0 parts of phthalein, 1.7 parts of sulfoniazid, 2 parts of ampicillin, 3 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition for treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, Radix Astragali extract, Radix Puerariae flavone, head are weighed by above-mentioned metering ratio Spore gram oxime, 3-n-butylphthalide, 3- Senkyunolide As, sulfoniazid, ampicillin, swertiamarin, sieve, Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mix 6min, control RSD≤5%, tabletting low temperature after mixing It is dried, at 6 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 4
A kind of pharmaceutical composition for treating community acquired pneumonia, according to the primary raw material of weight portion be：Ertapenem 7 Part, 22 parts of Radix Astragali extract, 7 parts of Radix Puerariae flavone, 5 parts of cefixime, 2 parts of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydrobenzenes 1.2 parts of phthalein, 1.8 parts of sulfoniazid, 3 parts of ampicillin, 4 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition for treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, Radix Astragali extract, Radix Puerariae flavone, head are weighed by above-mentioned metering ratio Spore gram oxime, 3-n-butylphthalide, 3- Senkyunolide As, sulfoniazid, ampicillin, swertiamarin, sieve, Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mix 8min, control RSD≤5%, tabletting low temperature after mixing It is dried, at 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 5
A kind of pharmaceutical composition for treating community acquired pneumonia, according to the primary raw material of weight portion be：Ertapenem 8 Part, 25 parts of Radix Astragali extract, 8 parts of Radix Puerariae flavone, 6 parts of cefixime, 2 parts of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydrobenzenes 1.4 parts of phthalein, 1.9 parts of sulfoniazid, 3 parts of ampicillin, 4 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition for treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, Radix Astragali extract, Radix Puerariae flavone, head are weighed by above-mentioned metering ratio Spore gram oxime, 3-n-butylphthalide, 3- Senkyunolide As, sulfoniazid, ampicillin, swertiamarin, sieve, Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mix 8min, control RSD≤5%, tabletting low temperature after mixing It is dried, at 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be realized in other specific forms.Therefore, no matter From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped Containing an independent technical scheme, this narrating mode of description is only that those skilled in the art should for clarity Using description as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art Understandable other embodiment.

Claims (6)

1. a kind of pharmaceutical composition for treating community acquired pneumonia, it is characterised in that the primary raw material according to weight portion is：Strategic point Ta Peinan 4-10 parts, Radix Astragali extract 16-24 parts, Radix Puerariae flavone 4-10 parts, cefixime 2-6 parts, 3-n-butylphthalide 1-3 Part, 3- normal-butyl -4,5- dihydro Phthalide 0.8-1.4 parts, sulfoniazid 1.5-1.9 parts, ampicillin 1-3 parts, swertiamarin 2-4 parts.
2. it is according to claim 1 treatment community acquired pneumonia pharmaceutical composition, it is characterised in that the treatment society The pharmaceutical composition of area's acquired pneumonia, according to the primary raw material of weight portion be：Ertapenem 6-7 parts, Radix Astragali extract 18-22 Part, Radix Puerariae flavone 5-7 parts, cefixime 3-5 parts, 3-n-butylphthalide 1-3 parts, 3- normal-butyl -4,5- dihydro Phthalide 0.9-1.2 Part, sulfoniazid 1.6-1.8 parts, ampicillin 1-3 parts, swertiamarin 2-4 parts.
3. it is according to claim 1 treatment community acquired pneumonia pharmaceutical composition, it is characterised in that the treatment society The pharmaceutical composition of area's acquired pneumonia, according to the primary raw material of weight portion be：7 parts of ertapenem, 20 parts of Radix Astragali extract, Pueraria lobota 6 parts of root flavone, 4 parts of cefixime, 2 parts of 3-n-butylphthalide, 1.0 parts of 3- normal-butyl -4,5- dihydros Phthalide, sulfoniazid 1.7 Part, 2 parts of ampicillin, 3 parts of swertiamarin.
4. it is a kind of as described in claim 1-3 is arbitrary treatment community acquired pneumonia pharmaceutical composition preparation method, its It is characterised by, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, Radix Astragali extract, Radix Puerariae flavone, cephalo gram are weighed by above-mentioned metering ratio Oxime, 3-n-butylphthalide, 3- Senkyunolide As, sulfoniazid, ampicillin, swertiamarin, sieve, machinery Add ultra-pure water after mixing, place in pharmacy mixer, mix 4-10min, control RSD≤5%, tabletting simultaneously do by low temperature after mixing Dry, at 4-10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
5. it is according to claim 4 treatment community acquired pneumonia pharmaceutical composition preparation method, it is characterised in that Mix 6min in concrete steps.
6. it is according to claim 4 treatment community acquired pneumonia pharmaceutical composition preparation method, it is characterised in that In concrete steps, temperature control is at 6 DEG C.
CN201611252847.4A 2016-12-30 2016-12-30 Drug composition for treating community-acquired pneumonia Pending CN106511452A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611252847.4A CN106511452A (en) 2016-12-30 2016-12-30 Drug composition for treating community-acquired pneumonia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611252847.4A CN106511452A (en) 2016-12-30 2016-12-30 Drug composition for treating community-acquired pneumonia

Publications (1)

Publication Number Publication Date
CN106511452A true CN106511452A (en) 2017-03-22

Family

ID=58336276

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611252847.4A Pending CN106511452A (en) 2016-12-30 2016-12-30 Drug composition for treating community-acquired pneumonia

Country Status (1)

Country Link
CN (1) CN106511452A (en)

Similar Documents

Publication Publication Date Title
Yu et al. Inhibitory effects of the Gentiana macrophylla (Gentianaceae) extract on rheumatoid arthritis of rats
CN108992663A (en) It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease
CN106511452A (en) Drug composition for treating community-acquired pneumonia
CN101757448A (en) Pure Chinese medicine sterilization anti-inflammatary suspension liniment and preparation method thereof
CN106420785A (en) Medicine composition for treating community-acquired pneumonia
CN101879219A (en) Chinese medicinal composition for treating mastitis of dairy cattle and preparation method thereof
CN103860474A (en) Doxycycline soluble powder production method
CN103550226B (en) Compound sulfamonomethoxine sodium injection as well as preparation method thereof
CN103083349A (en) Compound fluconazole gel for pets and preparation process thereof
CN105943541A (en) Long-acting breast injection agent for treating cow mastitis in dry period and preparation method of long-acting breast injection agent
CN101991587A (en) Compound sulfadiazine injection and preparation method thereof
CN102166334A (en) Externally-applied medicament for treating infantile eczema and senile pruritus and preparation method thereof
Radjeni et al. Antihypertensive Effect of Standardised Aqueous Ethanolic Extract of Ficus Deltoidea Trengganuensis in Spontaneously Hypertensive Rats
CN106727648A (en) A kind of medicine for treating community acquired pneumonia
CN106727591A (en) A kind of pharmaceutical composition for treating Streptococcus suis
CN102068642A (en) Medicinal composition for treating skin tinea and preparation method and application thereof
CN106727643A (en) A kind of Western medicine for treating bacterial pneumonia
CN106619666A (en) Pharmaceutical composition for treating swine dysentery
CN101947253B (en) External compound preparation for curing tinea corporis as well as preparation method and content measuring method thereof
CN106511440A (en) Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof
CN101467983B (en) Menatetrenone soft capsule and preparation method thereof
CN106727601A (en) One kind treats pleuritic medicine
CN103285034B (en) Medicine for treating chilblain and manufacturing method thereof
CN106727901A (en) A kind of pharmaceutical composition for treating chronic bronchitis
CN101756235A (en) Brain-invigorating pharmaceutical and edible traditional Chinese medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170322

WD01 Invention patent application deemed withdrawn after publication